Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

Rationale Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. Objectives To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P aeruginosa....

Full description

Saved in:

Bibliographic Details
Published in:	Thorax Vol. 68; no. 9; pp. 818 - 825
Main Authors:	Clancy, J P, Dupont, L, Konstan, M W, Billings, J, Fustik, S, Goss, C H, Lymp, J, Minic, P, Quittner, A L, Rubenstein, R C, Young, K R, Saiman, L, Burns, J L, Govan, J R W, Ramsey, B, Gupta, R
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group Ltd and British Thoracic Society 01.09.2013 BMJ Publishing Group LTD BMJ Publishing Group
Series:	Original article
Subjects:	Adolescent Adult Amikacin - administration & dosage Amikacin - adverse effects Analysis of Variance Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Antibiotics Bacterial Infection Child Cystic Fibrosis Cystic Fibrosis - complications Cystic Fibrosis - physiopathology Double-Blind Method Drug dosages FDA approval Female Forced Expiratory Volume Humans Infections Liposomes Male Microbial Sensitivity Tests Mortality Mutation Nebulizers and Vaporizers Patients Pharmacokinetics Pseudomonas aeruginosa Pseudomonas Infections - drug therapy Quality of Life Respiratory Infection Sputum - microbiology Young Adult United States > US Europe Cystic Fibrosis Bacterial Infection Respiratory Infection
ISSN:	0040-6376, 1468-3296, 1468-3296
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!